SE457143B - Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin - Google Patents

Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin

Info

Publication number
SE457143B
SE457143B SE8400851A SE8400851A SE457143B SE 457143 B SE457143 B SE 457143B SE 8400851 A SE8400851 A SE 8400851A SE 8400851 A SE8400851 A SE 8400851A SE 457143 B SE457143 B SE 457143B
Authority
SE
Sweden
Prior art keywords
coenzyme
carnitine
pharmaceutical composition
carnitin
acetyl
Prior art date
Application number
SE8400851A
Other languages
English (en)
Swedish (sv)
Other versions
SE8400851D0 (sv
SE8400851L (sv
Inventor
A Bertelli
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of SE8400851D0 publication Critical patent/SE8400851D0/xx
Publication of SE8400851L publication Critical patent/SE8400851L/xx
Publication of SE457143B publication Critical patent/SE457143B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SE8400851A 1983-02-16 1984-02-16 Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin SE457143B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH858/83A CH655005A5 (it) 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Publications (3)

Publication Number Publication Date
SE8400851D0 SE8400851D0 (sv) 1984-02-16
SE8400851L SE8400851L (sv) 1984-08-17
SE457143B true SE457143B (sv) 1988-12-05

Family

ID=4196830

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8400851A SE457143B (sv) 1983-02-16 1984-02-16 Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin

Country Status (11)

Country Link
US (1) US4599232A (ja)
JP (1) JPS59186914A (ja)
BE (1) BE898918A (ja)
CH (1) CH655005A5 (ja)
DE (1) DE3405581A1 (ja)
DK (1) DK165167C (ja)
FR (1) FR2543827B1 (ja)
GB (1) GB2137088B (ja)
IT (1) IT1170235B (ja)
NL (1) NL192778C (ja)
SE (1) SE457143B (ja)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209519B (it) * 1984-04-10 1989-08-30 Poli Ind Chimica Spa Composti ad attivita'cardiotrofica.
CH662505A5 (it) * 1985-04-30 1987-10-15 Seuref Ag Composizioni farmaceutiche ad azione protettiva vascolare.
CH670763A5 (ja) * 1985-08-02 1989-07-14 Seuref Ag
CH666183A5 (it) * 1985-08-06 1988-07-15 Seuref Ag Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
SE8703321D0 (sv) * 1987-08-27 1987-08-27 Sockerbolaget Ab Kostforsterkning
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
GB8907276D0 (en) * 1989-03-31 1989-05-17 Therapy Advisory Services Limi Health supplement
AT393954B (de) * 1990-02-28 1992-01-10 Bock Orthopaed Ind Verfahren und vorrichtung zur bestimmung von gebrauchseigenschaften eines prothesenschaftes
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
US5981601A (en) * 1992-05-28 1999-11-09 Centre For Molecular Biology And Medicine Method for enhancing cellular bioenergy
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
NZ338026A (en) * 1997-03-27 2001-09-28 Michael J Sole Nutritional composition comprising L-carnitine, ubiquione and taurine and use for treating organ systems
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5973004A (en) * 1997-04-04 1999-10-26 Howard; James R. L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
AU3221599A (en) * 1998-04-03 1999-10-25 Daily Wellness Company, The Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US6479069B1 (en) 1999-09-23 2002-11-12 Juvenon, Inc. Nutritional supplement for increased energy and stamina
US20070072927A1 (en) * 1999-09-23 2007-03-29 Vita Joseph A Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
US6335361B1 (en) 1999-11-03 2002-01-01 Juvenon Inc. Method of treating benign forgetfulness
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
WO2001058271A1 (en) * 2000-01-25 2001-08-16 Juvenon, Inc. Nutritional supplements for aged pets
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6579866B2 (en) 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
US7754205B2 (en) * 2001-05-10 2010-07-13 Kaneka Corporation Composition for transmucosal administration containing conenzyme Q as the active ingredient
CA2451163A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Agent for preventing or treating organ functional disorders and order dysfunction
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
EP1643863A2 (en) * 2003-07-10 2006-04-12 Carl A. Forest Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070225355A1 (en) * 2004-06-29 2007-09-27 Elixirin Corporation Dietary Compositions for Enhancing Metabolism and Reducing Reactive Oxygen Species
CA2610152C (en) * 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20050249803A1 (en) * 2005-06-03 2005-11-10 Udell Ronald G Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
SI1933821T1 (sl) * 2005-09-15 2020-11-30 Ptc Therapeutics, Inc. Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev
WO2007084839A2 (en) * 2006-01-13 2007-07-26 Elixirin Corporation Dietary methods and compositions for enhancing metabolism and reducting reactive oxygen species
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
US20080020022A1 (en) * 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
JP2009037201A (ja) * 2007-03-14 2009-02-19 Fujifilm Corp 感光性樹脂組成物、それを用いた硬化レリーフパターンの製造方法及び半導体装置
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
ES2306610B1 (es) * 2007-04-16 2009-09-11 Universidad De Sevilla Uso de la l-carnitina para el tratamiento de la hipertension arterial.
JP5377304B2 (ja) * 2007-06-22 2013-12-25 株式会社カネカ 補酵素ｑ１０含有組成物
JP5343002B2 (ja) * 2007-06-22 2013-11-13 株式会社カネカ 生理活性物質含有組成物
WO2009025277A1 (ja) * 2007-08-22 2009-02-26 Kaneka Corporation 還元型補酵素ｑ10の製造方法、ならびに、その安定化方法
KR101325374B1 (ko) * 2008-02-19 2013-11-08 가부시키가이샤 오츠까 세이야꾸 고죠 신체 기능의 회복에 유용한 경구 또는 경장 조성물
WO2010030607A1 (en) 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene

Also Published As

Publication number Publication date
SE8400851D0 (sv) 1984-02-16
BE898918A (nl) 1984-08-16
CH655005A5 (it) 1986-03-27
NL192778C (nl) 1998-02-03
IT8323559A0 (it) 1983-10-31
US4599232A (en) 1986-07-08
FR2543827B1 (fr) 1987-06-12
JPS59186914A (ja) 1984-10-23
NL192778B (nl) 1997-10-01
DK72284A (da) 1984-08-17
GB8403668D0 (en) 1984-03-14
DE3405581A1 (de) 1984-10-18
FR2543827A1 (fr) 1984-10-12
DK165167C (da) 1993-03-01
DK72284D0 (da) 1984-02-16
NL8400488A (nl) 1984-09-17
GB2137088A (en) 1984-10-03
GB2137088B (en) 1986-02-05
IT1170235B (it) 1987-06-03
DK165167B (da) 1992-10-19
JPH027572B2 (ja) 1990-02-19
DE3405581C2 (ja) 1992-10-22
SE8400851L (sv) 1984-08-17

Similar Documents

Publication Publication Date Title
SE457143B (sv) Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin
Feng et al. Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications
DE69909775T2 (de) Neue fettanaloge zur behandlung von diabetes
Modanloo et al. Analyzing mitochondrial dysfunction, oxidative stress, and apoptosis: potential role of L-carnitine
Danilenko et al. Metabolic cardioprotection: new conceptsin implementation of cardioprotective effects of meldonium
SK11252003A3 (sk) Kompozície biochemických zlúčenín zúčastňujúcich sa bioenergetického metabolizmu buniek a ich použitie
US6733793B2 (en) Oral composition with insulin-like activities and methods of use
EP0167115B1 (en) New derivatives of l-carnitine
JP2002542191A (ja) グルタチオンの吸収を増しかつその効果を補強するのに有用な、カルニチンおよびグルタチオン含有組成物
CN112292122A (zh) 使用烟酰胺腺嘌呤二核苷酸(nad+)前体和至少一种酮或酮前体的组合物和方法
NL8200022A (nl) Farmaceutische samenstelling, die gamma-butyrobetaine bevat, voor de behandeling van door l-carnitine gebrek teweeggebrachte syndromen.
KR20070108383A (ko) 지질 저하성 화합물
US20220288018A1 (en) Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
JPS62190190A (ja) Ｌ−カルニチンのホスホリルアルカノ−ルアミド誘導体類およびその医薬組成物
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
Minot The Relation of Calcium to the Toxicity of Carbon Tetrachloride in Dogs.
RU2636616C1 (ru) Комбинированное лекарственное средство для первичной нейропротекции
CN104869988B (zh) 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在治疗动脉粥样硬化中的用途
Gildea The Ketogenic Diet: A Summary.
ES2267796T3 (es) Uso de fibratos para la preparacion de un medicamento util en el tratamiento de insuficiencia cardiaca congestiva.
RU2595815C1 (ru) Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
RU2229293C1 (ru) Лечебно-профилактическое средство для использования в геронтологической практике
CA2924682C (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
JPS6253924A (ja) 心臓および筋代謝保護剤
US20060083779A1 (en) Diiodothyroacetic acid and method of use

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8400851-5

Format of ref document f/p: F

NUG Patent has lapsed